Chemistry: analytical and immunological testing – Nuclear magnetic resonance – electron spin resonance or other...
Reexamination Certificate
2009-01-20
2010-12-28
Gakh, Yelena G (Department: 1777)
Chemistry: analytical and immunological testing
Nuclear magnetic resonance, electron spin resonance or other...
C436S086000, C436S171000, C435S006120, C435S069900, C435S372000, C702S020000, C702S179000
Reexamination Certificate
active
07858390
ABSTRACT:
Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a colorectal cancer (CRC) patient is likely to benefit from a drug targeting an epidermal growth factor receptor pathway, such as monoclonal antibody EGFR inhibitors.
REFERENCES:
patent: 7736905 (2010-06-01), Roder et al.
patent: 2005/0048547 (2005-03-01), Zhao et al.
patent: 2005/0164218 (2005-07-01), Agus et al.
patent: 2005/0267689 (2005-12-01), Tsypin
patent: 2006/0029574 (2006-02-01), Albitar et al.
patent: 2007/0231921 (2007-10-01), Röder et al.
patent: 2009/0170216 (2009-07-01), Roder et al.
patent: WO 2004/012588 (2004-02-01), None
patent: WO 2005/010492 (2005-02-01), None
patent: WO 2005/098445 (2005-10-01), None
Written Opinion of the International Searching Authority in PCT/US2007/007467 dated Nov. 8, 2007.
International Search Report in PCT Application Publication No. WO 2007/126758, published Nov. 8, 2007.
Fleming et al. “Windowed mass selection method: a new data processing algorithm for liquid chromatography-mass spectrometry data”, Journal of Chromatography A, vol. 849, pp. 71-85 (1999). .
Senko et al., “Determination of monoisotopic masses and ion population for large biomolecules from resolved isotopic distribution”, Journal of the American Society for Mass Spectrometry, vol. 6, pp. 229-33 (1995).
Gras et al., “Improving protein identification from peptide mass fingerprinting through a parameterized multi-level scoring algorithm and an optimized peak detection”, Electrophoresis, vol. 20, pp. 3535-50 (1999).
Metro, et al., “Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC)”, Reviews on Recent Clinical Trials, vol. 1, No. 1, pp. 1-13 (2006).
Taguchi, et al., “Mass Spectrometry to Classify Non-Small-Cell Lung Cancer Patients for Clinical Outcome after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study”, Journal of the National Cancer Institute, vol. 99, Issue 11, pp. 838-46 (2007).
Ladanyi, et al., “Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond”, Modern Pathology, vol. 21, pp. S16-S22 (2008).
Office Action dated Feb. 6, 2009 in U.S. Appl. No. 11/396,328, filed Mar. 31, 2006.
Amendment and pending claims filed Apr. 7, 2009 in U.S. Appl. No. 11/396,328, filed Mar. 31, 2006.
U.S. Appl. No. 12/321,393, filed Jan. 20, 2009.
U.S. Appl. No. 12/321,392, filed Jan. 20, 2009.
Extended European Search Report in EP 07754043.3, dated Jun. 8, 2009.
U.S. Office Action dated Aug. 25, 2009 in U.S. Appl. No. 11/396,328, filed Mar. 31, 2006.
Lynch et al.,Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib, The New England Journal of Medicine, vol. 350, No. 21, pp. 2129-2139 (2004).
Alfassi,On the Normalization of a Mass Spectrum for Comparison of Two Spectra, American Society for Mass Spectrometry, vol. 15, pp. 385-387 (2004).
Bhanot et al.,A Robust Meta-Classification Strategy for Cancer Detection from MS Data, Proteomics, vol. 6, pp. 592-604 (2006).
Koenker et al.,Quantile Smoothing Splines, Biometrika vol., 81, pp. 673-680 (1994).
Eilers,Parametric Time Warping, Analytical Chemistry, vol. 76, No. 2, pp. 401-411 (2004).
Howard et al.Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis, Proteomics vol. 3, pp. 1720-1724 (2003).
Search Report and Written Opinion mailed Feb. 16, 2010 in PCT/US2009/006267, filed Nov. 20, 2009.
Daemen et al.Integrating Microarray and Proteomics Data to Predict the Response on Cetuximab in Patients with Rectal Cancer, Pacific Symposium of Biocomputing vol. 13, pp. 166-177 (2008).
Spano et al.Potential Predictive Markers of Response to EGFR-targeted Therapies in Colorectal Cancer, Critical Reviews in Oncology/Hematology vol. 66 No. 1, pp. 21-30 (2008).
Smith et al.Combination of SELDI-TOF-MS and Data Mining Provides Early-stage Response Prediction for Rectal Tumors Undergoing Multimodal Neoadjuvant Therapy, Annals of Surgery vol. 245 No. 2 pp. 259-266 (2007).
Reymond at al.Expression and Functional Proteomics Studies in Colorectal Cancer, Pathology Research and Practice, Gustav Fischer, Stuttgart, DE, vol. 200 No. 2 pp. 119-127 (2004).
Oda et al.A Comprehensive Pathway Map of Epidermal Growth Factor Receptor Signaling, Molecular Systems Biology vol. 1 pp. 1-17 (2005).
Duncan et al.Quantitative Matrix-assisted Laser Desorption/lonization Mass Spectrometry, Briefings in Functional Genomics and Proteomics-Special Issue: Topics in Quantitative Biological Mass Spectrometry vol. 7 No. 5 pp. 355-370 (2008).
Extended European Search Report dated Aug. 25, 2010 in European Application No. 10003343.0.
Bhanot et al.A robust meta-classification strategy for cancer detection from MS dataProteomics, vol. 6, NR 2, pp. 592-607 (Jan. 2006).
Reyzer et al.MALDI mass spectrometry for direct tissue analysis: a new tool for biomarker discovery, Journal of Proteome Research vol. 4, No. 4, pp. 1138-1142 (2005).
Yanagisawa et al.Proteomic patterns of tumour subsets in non-small-cell lung cancer, The Lancet, vol. 362, pp. 433-439 (Aug. 9, 2003).
Grigorieva Julia
Röder Heinrich
Tsypin Maxim
Biodesix, Inc.
Gakh Yelena G
McDonnell Boehnen & Hulbert & Berghoff LLP
Xu Robert
LandOfFree
Selection of colorectal cancer patients for treatment with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selection of colorectal cancer patients for treatment with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selection of colorectal cancer patients for treatment with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4236884